Apixaban for oral antithrombotic therapy: is a new era coming?
Apixaban, a new oral inhibitor of activated factor Xa, may simplify antithrombotic therapy with fixed doses and no necessity for coagulation monitoring. Apixaban is non-inferior to conventional therapy (enxoaparin, followed by warfarin) with lower risk of major bleeding in the treatment of acute ven...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452060/ |